NORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million upfront ...

In the past week, several Gubra board members, including co-founder Jacob Jelsing and CEO Markus Rohrwild, disclosed insider purchases totaling more than DKK 16 million, as officially reported under ...

AbbVie (NYSE:ABBV) has entered into a license deal with Danish biotech Gubra A/S to develop the latter’s experimental obesity treatment. GUB014295, currently in a Phase 1 clinical trial, is a ...

AbbVie will pay Gubra $350 million upfront, with up to $1.875 billion in milestone payments. GUB014295, an amylin analog for obesity, is currently in Phase 1 trials. Geopolitical tensions, Fed ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist Gubra A/S. In addition, there will ...

Today, Gubra releases its results for the third quarter of 2025. In September, Gubra welcomed Markus Rohrwild as our new CEO. The ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...